# A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

> **NCT00872014** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 60 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Inoperable Hepatocellular Carcinoma

## Interventions

- **DRUG:** AMG 386
- **DRUG:** AMG 386
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00872014
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-10
- **Final completion:** 2015-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00872014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00872014, "A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00872014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*